SET(ER/PR): a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer

There is a clinical need to predict sensitivity of metastatic hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer to endocrine therapy, and targeted RNA sequencing (RNAseq) offers diagnostic potential to measure both transcriptional activity and functional mutation. We developed th...

Descripción completa

Detalles Bibliográficos
Autores principales: Sinn, Bruno V., Fu, Chunxiao, Lau, Rosanna, Litton, Jennifer, Tsai, Tsung-Heng, Murthy, Rashmi, Tam, Alda, Andreopoulou, Eleni, Gong, Yun, Murthy, Ravi, Gould, Rebekah, Zhang, Ya, King, Tari A., Viale, Agnes, Andrade, Victor, Giri, Dilip, Salgado, Roberto, Laios, Ioanna, Sotiriou, Christos, Marginean, Esmeralda C., Kwiatkowski, Danielle N., Layman, Rachel M., Booser, Daniel, Hatzis, Christos, Vicente Valero, V., Fraser Symmans, W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6542807/
https://www.ncbi.nlm.nih.gov/pubmed/31231679
http://dx.doi.org/10.1038/s41523-019-0111-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6542807/
https://www.ncbi.nlm.nih.gov/pubmed/31231679
http://dx.doi.org/10.1038/s41523-019-0111-0

Ejemplares similares